Abstract

Objectives: We evaluated the impact of refractory or unexplained chronic cough (RCC/UCC) frequency on health-related quality of life (HRQoL). Methods: A Phase 2b, 12-week, double-blind RCT included RCC/UCC subjects (cough duration ≥1 year; baseline VAS ≥40 mm) (NCT02612610). Treatment groups (placebo, gefapixant 7.5mg, 20mg, and 50mg) were pooled for this analysis. A sound-recording device (VitaloJAKTM, Vitalograph, Ltd.) was used to assess Awake Cough Frequency (aCF). The Leicester Cough Questionnaire (LCQ; Total, Physical, Psychological and Social scores) assessed HRQoL. Mean baseline LCQ scores across tertiles of aCF (0-33 [lowest], 34-66, and 67-100th percentiles) and baseline to Week 4 changes across aCF responder groups (≥30% reduction vs 1.5, >0.5, and >0.6 on the Total, Physical, Psychological/Social domains are considered meaningful. Results: LCQ and aCF were completed by 251 subjects. At baseline, mean (SE) Total LCQ scores were highest (better) for the lowest tertile of aCF: 13.1 (0.31), 11.2 (0.31), and 10.7 (0.31) for the 0-33, 34-66, and 67-100 percentiles, respectively. A similar trend was observed for the baseline LCQ domain scores. After 4 weeks of treatment, aCF responders had an LS mean (SE) LCQ Total score increase of 4.2 (0.25) while non-responders had an increase of 1.2 (0.28) (p Conclusion: RCC/UCC subjects with higher aCF report worse HRQoL. Clinically meaningful improvements in aCF result in improvements in HRQoL that are consistent with LCQ meaningful change thresholds.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call